28 April 2022Press Releases
The Corporate Finance team at James Cowper Kreston recently provided financial and tax due diligence to Chiltern Capital for their investment in Surepharm.
Founded in 1990, Burton-on-Trent based Centaur Healthcare Limited (trading as “Surepharm”) provides outsourced formulation, development, manufacturing and packaging of products for its customers in the UK and overseas. They currently specialise in producing solid dose tablets and capsules, including niche medicines, controlled drugs and veterinary products.
The investment from Chiltern Capital will support Surepharm to enhance its formulations and development offering, along with funding for capex investment into new dosage forms. This will enable Surepharm to provide both existing and new customers with an end-to-end service, from drug development through to a packaged commercial product across a broad range of product types.
Chiltern's investment was supported by co-investors Souter Investments and Bluester Capital. Debt finance was provided by Thincats.
Brad McAvoy, Corporate Finance Partner at James Cowper Kreston said “We were delighted to work with Joe Bennett and the team at Chiltern Capital on their investment in Surepharm. The investment will assist Surepharm to achieve its growth strategy and expand its market position.”